Golimumab
Golimumab, a biologic. Fully human IgG1κ mAb generated by transgenic mouse platform, binds both soluble and transmembrane TNFα. Monthly… Subcutaneous half-life 12 d.
Fully human IgG1κ mAb generated by transgenic mouse platform, binds both soluble and transmembrane TNFα. Monthly SC dosing improves adherence vs adalimumab q2w. Once-monthly cadence makes golimumab attractive for patients with stable disease.
PK: ABSORPTION RATE AUTHORED FROM THE SIMPONI LABEL. This row carried no ka, so the solver substituted 1.0/h and put the peak at 6.0 h. Source, verbatim from the current FDA label (DailyMed setid f86cb4a7-c358-4136-ae57-b32bda9bba00): "Following subcutaneous administration of SIMPONI to healthy subjects and patients with active RA, the median time to reach maximum serum concentrations (T max ) ranged from 2 to 6 days." RANGE: the shorter endpoint is taken. PUBMED HAS THIS NOWHERE — 27 targeted searches across two passes returned four usable peak times for this whole class, because Tmax is a label figure that rarely reaches an abstract. A regulatory label is already a first-class source in this schema. With the stored half-life fixing ke, Tmax solves uniquely for ka by inverting the model own definition, ln(ka/ke)/(ka-ke) = Tmax — ARITHMETIC, NOT AN ESTIMATE — giving 0.07369/h, which reproduces 48 h on substitution. EXPOSURE IS UNCHANGED: the absorption rate cancels out of AUC, so only the shape moves.
Pharmacokinetics
- Subcutaneous — t½ 12.0 d · F 51% · ka 0.07369 h⁻¹ · Vd 7.7 L
- IV — t½ 12.0 d · F 100% · Vd 7.7 L
Sources: PMID:31982148, PMID:20519961